Skip to main content

Spanish Government Moves To Formally Consider Medical Efficacy Of Cannabis

Last week, the Spanish Congressional Health and Consumer Affairs Commission Committee met to consider exploring the medical efficacy of cannabis. Will this finally move the needle on some type of formal, final Spanish reform?

It is odd looking at the developments in Spain with an American perspective but on the European side of the discussion. In some ways, the situation in the country is analogous to the period of reform that began to percolate about 2014. Namely, two American states had voted to change their state constitutions to make recreational cannabis legal. In the meantime, federal reform of even the medical kind remained elusive. To some extent this is the impact of the lobbying power of the recreational movement in the United States and the lack of a formal underlying federal healthcare system. However, it is also a testament to the general reluctance of federal level authorities to even acknowledge the same.

In Spain, a similar kind of situation is brewing. 

The club movement really began picking up steam along with the American recreational movement. The two main Spanish states in which clubs are found today are the two most independent. Basque country and the Catalan (Barcelona). 

The club movement has been hurt by Covid, but it is still operating, around the edges of “the law.” In the meantime, one of the organizers of the same must report to jail nightly after his human rights case was refused by the court in Strasbourg. However, moving events across the EU (see medical reform in Germany, and now France) as well as Albert Tió’s struggle domestically has ignited, finally, a desire on the federal level in Spain to address the overall issue.

Could Federal Reform Help Solve the Club Problem?

It appears that the powers that be in Spain might have gotten the memo that the entire situation as it stands, is more than a bit ridiculous. The Comision de Sanidad y Consumo has ample evidence, including at this point many European countries that have recognized the drug as having medical efficacy. At the EU level, CBD is no longer considered even a narcotic.

While it is unlikely that the Spanish government will move quickly, it is unlikely that Spanish authorities will not push the issue forward, finally, within the next 12 months. And by tipping a hand to modern science it is also likely that the entire club conversation will also then get added to the mix. Currently, there is no reliable data on what percentage of club clients are patients.

There is already a rec market in Holland. Within a year there will be two more (in Luxembourg and Switzerland).

While it is unlikely in other words that anything on a federal level will be transformative by the admission of medical efficacy by the Spanish government, it appears that the time has come, finally, for Spain to enter the 21st century on the basic issue of federal medical reform. It is unlikely that the clubs will be closed when that happens. And further, very possible that this will be the final trigger to push for regulation of the club system (like what has been seen in Holland).

Be sure to book your tickets to the International Cannabis Business Conference when it returns to Europe this summer.

It’s Critical That German CBD Law Matches EU Law

After a brew ha ha over hemp tea that made its way to federal court, there is a renewed call domestically to homogenize German law with European ruling. Is “Trickle Down Reform” from the EU a better way to handle cannabis reform?

In an indeterminate case in March, a case involving hemp tea made its way to the German federal court but the ruling did not clear up the status of hemp in the country. It is still considered a “narcotic” under German law (even though on a European level this has now been cleared up).

The case however is indicative of a larger problem that exists across Europe. The first is that the status of cannabis generally has not been determined across the region. The ruling on CBD by the European Commission last fall may have given the EU its “2018 Farm Bill” but there are much bigger issues to deal with still in the room. Think, for example, how largely ineffective the U.S. legislation has been with dealing with the vast majority of problems facing just the American industry.

This is why the European Cannabis Association was formed (to begin to move the bigger ticket items forward from cultivation through end distribution). There is an urgent need to do the same as even the Spanish government is finally moving (as the last larger economy in Europe) to recognize the medical efficacy of the plant.

Beyond that, however, there is then the problem of adoption of sovereign states of any European-wide decision on cannabis. In this case, the cry has been taken up by the hemp company involved in the German case as well as the German Cannabis Industry Association.

It is clear that it is critical that German law be in alignment with EU-wide decrees on cannabis – but what is the best approach to make this happen? Is hemp the real door opener, or rather cannabis generally? And further, now that EU policy has been set on the same, why focus on anything other than comprehensive reform and policies?

If the US is any indication, it is discussions about the entire plant which make a real difference. Without regulation on a federal level, the U.S. states are proceeding on policies that themselves will have to be changed again with a national policy change. The “hemp exception” made zero difference in any state in the U.S. when it has come to actual reform. Indeed, this has been used as window dressing to stave off the larger discussions – namely all of the ones involved in comprehensive regulation except for the level of THC allowed in hemp.

This means that in Europe, it is critical for sovereign organizations and groups to begin to unite under a single umbrella to push reform at a regional level, and in Brussels. And for the whole plant, not just part of it.

Indeed, in the recent tea case, it was the EU decision that was the deciding case law, not the German Narcotics Act. While it is painful for individual members of the industry to get caught in changing gears of regulatory requirements, it is also critical for the companies within it to realize that organization in Europe must happen regionally first, not locally, for real change to come at a legislative and legal level now.

Be sure to book your tickets now to the International Cannabis Business Conference when it returns to Europe this summer.

Revised Medical Cannabis Bill Close To Being Filed In Bahamas

Legal medical cannabis industries are operating all over the planet now thanks to reform victories in recent years and the tireless work of activists and advocates that made those reform victories possible.

Medical cannabis is even being exported across international borders from one country to another, often involving transport across an ocean or two.

With that being said, there are still many countries that continue to prohibit medical cannabis in all of its forms. One of those countries is the Bahamas.

Fortunately, a medical cannabis measure appears to be coming soon. Per The Nassau Guardian:

Following consultation with the Bahamas Christian Council (BCC), various medical professionals and Bahamians in the cannabis business abroad, Attorney General Carl Bethel said yesterday he expects to submit a redrafted medical marijuana bill to a Cabinet subcommittee for review this weekend.

Once the committee reads through the new draft, Bethel said he may present the bill to Cabinet for final approval either next week or the following week.

“(Retired Justice) Dame Anita Allen is working with the Law Reform Commission now to put all of the different suggestions that we deem to be workable, because not everything suggested is workable at the present time, into the redraft of the bill,” Bethel said.

In the summer of 2018 recommendations were offered up by the CARICOM Regional Commission on Marijuana to decriminalize cannabis in the Bahamas.

Later, the Bahamas National Commission on Marijuana recommended legalizing cannabis for medical use. As of right now, it appears that only the medical cannabis provisions will be included in the looming legislation, although we won’t know until the measure is officially submitted.

First Cannabis Patient Makes Bid For Home Grow In Spain

A 49-year-old male patient has made his application for medical home grow to the Spanish Medicines Agency public

Juan Manuel Rodriguez, a Gen X Spanish citizen, has just made his application for a cannabis home grow license to the Spanish Medicines Agency public. Rodriquez has been confined to a wheelchair for thirty years after a tragic accident when he was 19.

He is making his legal claim under the 1967 Spanish law (in other words a pre-constitutional law) which allows for the use of medical cannabis if specifically authorized by the federal drugs and medical devices agency.

The plea could not come at a more contentious time.

The Situation in Spain

Much like the Dutch market, the Spanish cannabis club environment has developed within the grey areas of national law. The most recent high-profile case in court, filed by activist Albert Tió, at the European level, went down in flames last month. In the meantime, the club scene is caught in disarray because of the Pandemic domestically. And beyond Spanish borders the issue of regulation is also moving in several European countries (see Holland, as of next year, both Luxembourg and Switzerland).

The activists on the ground know there is an opening – and are continuing to support legal challenges and applications of all sorts – including Rodriguez’ – and presumably those who will follow suit.

The application may finally be the tipping case to move the entire conversation forward – but it also may not. While severely disabled patients usually have a good case to make – and have often moved the needle (see Germany as a prime example of the same on a European level) – it is most often not adults but children who manage to put enough political pressure on governments to change the law. See the UK, but also see Israel where, in 2014, enough parents threatened to immigrate to the American state of Colorado that the Israeli government changed its policies within weeks.

That is not likely to be the case in Spain. However, what is clear is that the status quo is increasingly being challenged by individuals who obviously have a medical and economic need. 

Even in Spain in other words, prohibition is dying a death of a thousand cuts – one challenge at a time.

Be sure to book your tickets to the International Cannabis Business Conference events in Europe in 2021!

Argentina Begins To Move Seriously On Medical Reform

The world’s eighth-largest country moves forward on legislation to create a federal industry.

Here is the interesting thing about sovereign cannabis reform – It is rather unsurprisingly beginning to reflect the national cultures that allow the same. How that begins to impact the international discussion is still a conversation in progress.

Here is one thing to be sure of about the decision of Argentina to begin to formalize the medical cannabis discussion on a federal basis.

This is the country that created the first animated feature film, the one with the highest number of plastic surgeries in the world and the one with the highest number of psychologists per capita. It is also the one that eats gnocchi on the 29th of every month.

In other words, prepare to be surprised. While certain aspects of reform look the same just about everywhere now adays, there are still going to be interesting riffs on a theme.

The Drug War is finally over, including in Latin America – and the Spanish twist to this tango is about to add to the entire debate in a way that has not been seen (yet) – and will reverberate in other countries (starting with Spain itself).

The Argentine Specifics

While the law is still in draft form and being revised by several agencies, here is what is shaping up as important elements of the same: The country will create a formal, provincial medical cannabis laboratory, continue to develop its user registry and set up an advisory council to set standards and guidelines for the therapeutic use of cannabis.

The other aspects of all of this, namely a plan to industrialize the production of cannabis and further how to prioritize “free” distribution to those who are the sickest, but none have been decided yet.

Regardless, the fact that all of this is on the table means the discussion is not only moving seriously, but likely to impact cannabis conversations in several other countries. That includes intercontinental Exim throughout Latin America. It also almost by definition includes Canada and Europe.

Don’t Cry for Me…

The forward development of the reform question is a good sign – especially in a country which has taken the slow boat to this entire conversation over the last few years. The patient registry got started last fall. It is clearly now part of federal plans on a much broader scale. And while it won’t happen tomorrow, reform is clearly not only on the table, but rolling forward slowly.

Be sure to book your seats now for the International Cannabis Business Conference when it comes back to Germany in July.

French Medical Cannabis Public Policy Experiment Is Underway

At one point France had one of the worst cannabis policies in Europe, with personal possession carrying a penalty of jail time and thousands of dollars in fines.

Fortunately, that changed recently and now cannabis possession is decriminalized and carries a much lower fine. It’s obviously not as good as outright legalization, but it’s certainly an improvement compared to the previous policy.

The nation-wide decriminalization policy change came after a public policy experiment in which certain parts of France instituted a temporary decriminalization policy, and after that proved to be successful, the policy was enacted across France.

Another cannabis-related public policy experiment is underway in France, this time focusing on medical cannabis. Per ABC:

If lawmakers and regulators in France take a truly objective approach to this experiment, it’s virtually guaranteed that the experiment will prove to be successful.

After all, a number of countries have already legalized cannabis for medical use, including and especially in Europe. If medical cannabis can work in those countries, then so too can it work in France.

The suffering patients in France deserve to have safe, legal access to a proven medicine, and to be governed by cannabis policies that are based on science, logic, and compassion.

CBD Is No Longer A “Narcotic” In Slovakia

The country becomes the last in the EU to remove cannabidiol from its national list of “psychotropics” and to legalize its use.

While there are often kudos paid to being “first” – in anything, and far from cannabis – there are also those who deserve attention for taking the tortoise route – especially when they finally get there. Slovakia has now joined the rest of the EU and finally seen the light on CBD.

As of March 18, the Ministry of Health submitted a proposal to legalize CBD on the grounds that according to the UN, CBD is not listed as a psychotropic medicine. The European Commission also decided the same last fall – but those are just the details in the weeds of all of this.

That said, because the country is also now watching what the EU will do on extracts and oils, it is also clear that there is starting to be a movement at the sovereign national level to normalizing the entire cannabis conversation – even if it starts with CBD. And that further, failing input from the democratic process domestically (citizens and advocates), the EU will begin to play an increasingly important role in setting policies that affect the entire industry and in every country in Europe.

Why Is the EU Level Bureaucracy Increasingly Important for Reform?

For those who are less than enthused about bureaucracy generally, the prospect of “reform” at the EU level, especially on this issue, is a groan fest. This particular part of the world is the least democratic, most paper-strewn, rules-driven part of the planet. Federal U.S. politics look “easy” compared to this. 

Anyone with any experience in waiting for the EU-level coordinated Covid vaccine to roll out any time soon (in other words everyone) can understand viscerally what the holdups have been on the cannabis front.

However, just like the overdue attention, those at the top of things are getting on the vaccine discussion, the cannabis conversation now brewing is fundamental and increasingly inescapable.

The issues of homogenizing the market, on standards, from simple hemp and CBD oil to medicine and beyond that, full and final reform are finally on the table.

Slovakia, in other words, might be the last to recognize what CBD actually is – but it is coming at a time when further discussions, and of a watershed kind – not just in one European country – but all of them – are taking place. And it is, of course, long overdue.

Be sure to book your tickets now for the International Cannabis Business Conference investor forum in Austin and of course, when the International Cannabis Business Conference returns to Berlin in July!

Covid Pandemic Puts Isle Of Man Medical Cannabis Program On Hold

Authorities have delayed a program to authorize doctors to prescribe cannabis describing it as “low priority” during the Pandemic.

The islands around the UK are having a quiet cannabis revolution. Places like the Channel Islands of Guernsey and Jersey and indeed the Isle of Man (off the southern tip of the UK) are moving forward to enact reform of at least the medical kind as green economic development if not critical healthcare for island residents. Unfortunately, plans to enact reform on the Isle of Man have just hit a snag. Health Minister David Ashford has said that the plan is still “on the agenda” but pushed because of the Pandemic.

Ashford said that there were “greater priorities” than introducing new cannabis legislation to the island. Ashford also cited reticence of GPs to prescribe the drug was also an issue.

Currently, per UK law, only specialists can prescribe the drug. This means that the initial visit and screening process is also much more complicated for both patients and the NHS. On a small island, this process gets even tougher.

Critics have suggested that this program should go ahead on schedule anyway and indeed have cited the model followed on the island of Jersey where a small number of general practitioners who operate out of clinics, can prescribe.

Untangling a hundred years of prejudice

Delaying the inevitable, and for any reason, appears to the watchword of just about all authorities, wherever they are, on the topic of reform. This has been true for most of the Pandemic, despite noted successes on a global level and the EU one (see the WHO decision and the European Commission decisions).

Regardless, it is also clear that reform is going to be in the air this spring and in several different ways. Doctors themselves are hardly above the din (in both the UK and Europe). The resulting pressures is forcing the conversation forward, even if, as in this case, step by step and painfully. And with plenty of delay.

And while these circular arguments are still in fashion (no reform equals no doctor education), they are becoming thankfully, rather rarer.

The Intersections of Covid and Cannabis

As the Pandemic drags on and governments repeatedly drop the ball on rolling out Covid medication, more and more focus is coming to bear on the process of cannabis legalization and, at minimum, why at least medical cannabis reform is not rolling right along with it. Including the increasing realization that cannabis might impact Covid symptoms.

Be sure to book your tickets now to the International Cannabis Business Conference conference for investors in Austin as well as the return of the International Cannabis Business Conference to Berlin this summer!

European Cannabis Association Is Working Towards A Harmonized Regulatory Framework

Cannabis is medicine. That is a phrase that has always been true, yet was not always reflected in public policy. The cannabis plant was prohibited across the globe for many years and subjected to a tremendous amount of negative propaganda and stigma.

Fortunately, the truth about the cannabis plant and its wellness properties could not be contained forever. Activists across the planet worked extremely hard to cut through the propaganda and get the facts out to society regarding medical cannabis.

Myth after myth was debunked. As public awareness about medical cannabis spread, so too did cannabis reform victories and compassion and healing as patients started to gain safe access to medical cannabis.

Few if any medications are as dynamic as cannabis-based medicines. As tens of thousands of peer-reviewed studies have found, the cannabis plant can be used to successfully treat a number of conditions. Those studies are also backed up by the personal experiences and testimonials of countless patients.

Medical cannabis is now, thankfully, being embraced by more and more countries throughout the world, including and especially in Europe. The medical cannabis industry is booming on the European continent, with domestic markets ramping up, as well as imports and exports.

With that being said, Europe’s medical cannabis industry is still in its infancy by many measures. As of right now, policies across the continent are a bit of a patchwork of sorts and there is not a balanced framework in place for medical cannabis products like there is with other legal medicines.

Getting the right Europe-wide medical cannabis framework of policies, rules, and regulations in place is vital to the future success of Europe’s medical cannabis industry. Europe is home to roughly 750 million people, many of which will benefit from safe access to medical cannabis. Those suffering patients deserve to have a medical cannabis industry that helps them as much as possible, and that will only happen if entrepreneurs are operating in a business environment that is conducive to helping them succeed.

That’s where the European Cannabis Association (ECA) comes in. ECA recently launched and will focus on consulting and helping European lawmakers and regulators craft standards for the production of medicinal cannabis, among other things.

“The use of medical cannabis has a very high potential and it has become one of the most important economic topics in recent years. Nevertheless, there is still no harmonized regulatory framework that governs the trade in medical cannabis at the EU level.” stated ECA member Peter Homberg. Homberg is the Head of German Life Sciences Practice at Dentons, as well as Head of the European Cannabis Sector Group at Dentons.

“The ECA addresses exactly this area and offers support in consulting and developing uniform standards for the production of medical cannabis. In particular, the ECA informs its members about the current EU framework conditions in the field of medical cannabis, stays in contact with and influences on policymakers and regulatory bodies with the aim of achieving appropriate framework conditions in particular on a European level, represents the European medical cannabis industry in an international environment, develops and supports international networks and organizes and realizes industry conferences.” Homberg went on to say.

Getting the right medical cannabis framework in place in Europe is vital because it will steer the young industry well into the future. Initial rules and regulations will inevitably change, however, those changes will presumably be incremental and a future complete overhaul will be unlikely. Lawmakers and regulators need to get it right the first time.

A collective industry voice will be key to the ongoing regulatory framework process. Cannabis opponents and uneducated skeptics will no doubt have a seat at any regulatory table, and they will certainly have collective voices lobbying all over Europe. That lobby presence has to be met with a credible collective voice representing the medical cannabis industry.

Membership to the European Cannabis Association is open to all stakeholders in the medical cannabis industry, whether they are large companies or small and medium-sized enterprises, including start-ups. Interested parties can find out more, including how to join ECA, at EuropeanCannabisAssociation.com.